Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 2017, Article ID 5091027, 6 pages
https://doi.org/10.1155/2017/5091027
Research Article

Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

1Department of Molecular Basis of Human Genetics, Institute of Molecular Genetics, Russian Academy of Sciences, 2 Kurchatov Sq., Moscow 123182, Russia
2Department of Chemistry of Physiologically Active Compounds, Institute of Molecular Genetics, Russian Academy of Sciences, 2 Kurchatov Sq., Moscow 123182, Russia

Correspondence should be addressed to Anastasiya Kasian; ur.sar.gmi@naisak

Received 13 October 2016; Revised 19 December 2016; Accepted 16 January 2017; Published 9 February 2017

Academic Editor: Enzo Emanuele

Copyright © 2017 Anastasiya Kasian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Pemberton and M. D. Fuller Tyszkiewicz, “Factors contributing to depressive mood states in everyday life: a systematic review,” Journal of Affective Disorders, vol. 200, pp. 103–110, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. M. C. Gravielle, “Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance?” Pharmacological Research, vol. 109, pp. 92–100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Kolomin, M. Shadrina, P. Slominsky, S. Limborska, and N. Myasoedov, “A new generation of drugs: synthetic peptides based on natural regulatory peptides,” Neuroscience and Medicine, vol. 4, pp. 223–252, 2013. View at Publisher · View at Google Scholar
  4. I. P. Ashmarin, “Glyprolines in regulatory tripeptides,” Neurochemical Journal, vol. 1, no. 3, pp. 173–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. I. P. Ashmarin, G. E. Samonina, L. A. Lyapina et al., “Natural and hybrid ("chimeric") stable regulatory glyproline peptides,” Pathophysiology, vol. 11, no. 4, pp. 179–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. N. Sollertinskaya, M. V. Shorokhov, M. M. Kozlovskaya, I. I. Kozlovskii, and K. V. Sudakov, “Compensatory and antiamnestic effects of heptapeptide Selank in monkeys,” Journal of Evolutionary Biochemistry and Physiology, vol. 44, no. 3, pp. 332–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. P. Semenova, I. I. Kozlovskii, N. M. Zakharova, and M. M. Kozlovskaia, “Experimental optimization of learning and memory processes by selank,” Eksperimental'naia i Klinicheskaia Farmakologiia, vol. 73, no. 8, pp. 2–5, 2010. View at Google Scholar
  8. I. I. Kozlovskii and N. D. Danchev, “The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats,” Neuroscience and Behavioral Physiology, vol. 33, no. 7, pp. 639–643, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. B. Seredenin, Y. A. Blednov, B. A. Badyshtov, M. L. Gordey, and Y. A. Nagovitsina, “Pharmacogenetic analysis of mechanisms of emotional stress: effects of benzodiazepines,” Annali dell'Istituto Superiore di Sanità, vol. 26, no. 1, pp. 81–87, 1990. View at Google Scholar
  10. S. B. Seredenin, M. M. Kozlovskaia, I. Blednov et al., “The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction,” Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova, vol. 48, no. 1, pp. 153–160, 1998. View at Google Scholar
  11. T. V. V'yunova, L. A. Andreeva, K. V. Shevchenko, V. P. Shevchenko, and N. F. Myasoedov, “Peptide regulation of specific ligand-receptor interactions of GABA with the plasma membranes of nerve cells,” Neurochemical Journal, vol. 8, no. 4, pp. 259–264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Liu, C. Xu, X. Wu et al., “Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation,” Neuroscience, vol. 294, pp. 193–205, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. M. Kozlovskaya, I. I. Kozlovskii, E. A. Val'dman, and S. B. Seredenin, “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress,” Neuroscience and Behavioral Physiology, vol. 33, no. 9, pp. 853–860, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. I. P. Ashmarin, K. E. Baglikova, S. E. Edeeva et al., “A comparative analysis of the distribution of glyprolines after their administration by different ways,” Russian Journal of Bioorganic Chemistry, vol. 34, no. 4, pp. 415–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. A. Zolotarev, A. K. Dadayan, O. V. Dolotov et al., “Evenly tritium labeled peptides in study of peptide in vivo and in vitro biodegradation,” Russian Journal of Bioorganic Chemistry, vol. 32, no. 2, pp. 166–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Willner, “Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation,” Psychopharmacology, vol. 134, no. 4, pp. 319–329, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. M. C. Schweizer, M. S. Henniger, and I. Sillaber, “Chronic mild stress (CMS) in mice: of anhedonia, ‘anomalous anxiolysis’ and activity,” PloS One, vol. 4, no. 1, p. e4326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. S. Rossler, C. Joubert, and G. Chapouthier, “Chronic mild stress alleviates anxious behaviour in female mice in two situations,” Behavioural Processes, vol. 49, no. 3, pp. 163–165, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Strekalova, R. Spanagel, O. Dolgov, and D. Bartsch, “Stress-induced hyperlocomotion as a confounding factor in anxiety and depression models in mice,” Behavioural Pharmacology, vol. 16, no. 3, pp. 171–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Strekalova and H. W. Steinbusch, “Measuring behavior in mice with chronic stress depression paradigm,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 34, no. 2, pp. 348–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Volkova, M. Shadrina, T. Kolomin et al., “Selank administration affects the expression of some genes involved in GABAergic neurotransmission,” Frontiers in Pharmacology, vol. 7, p. 31, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. V. E. Medvedev, O. N. Tereshchenko, A. Israelian et al., “A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders,” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 114, no. 7, pp. 17–22, 2014. View at Google Scholar
  23. A. A. Zozulia, G. G. Neznamov, T. S. Siuniakov et al., “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia,” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008. View at Google Scholar
  24. V. E. Medvedev, O. N. Tereshchenko, N. V. Kost et al., “Optimization of the treatment of anxiety disorders with selank,” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, vol. 115, no. 6, pp. 33–40, 2015. View at Publisher · View at Google Scholar · View at Scopus